Showing 8681-8690 of 9964 results for "".
- Mirvaso Now Available in the UKhttps://practicaldermatology.com/news/20140417-mirvaso_now_available_in_the_uk/2459269/Mirvaso (brimonidine) 3mg/g gel, an alpha-2 adrenergic agonist indicated for the symptomatic treatment facial erythema associated with rosacea in adult patients, is now available in the UK. The active ingredient, brimonidine, restricts excessive blood f
- Residents Provided with Online Education by ASDShttps://practicaldermatology.com/news/20140416-residents_provided_with_online_education_by_asds/2459270/Kyle M. Coleman, MD, has developed a dermatologic surgery educational series as part of the ASDS Future Leaders Network. The "Better Surgical Education" video series, focusing on dermatologic surgery topics and procedures, will provide additional education opportunities for residency programs.
- L'Oreal Partners with Celebrities for New Melanoma PSAhttps://practicaldermatology.com/news/20140416-loreal_partners_with_celebrities_for_new_melanoma_psa/2459271/L'Oréal is partnering with Melanoma Research Alliance (MRA) to launch the campaign "It's THAT Worth It™." Diane Keaton, skin cancer survivor will be featured urging women of all skin tones to use sunscreen. Other celebrities join Keaton in this campaign in print and broadcast PSAs
- DNA to Host Annual Meeting in Orlando, May 1-4https://practicaldermatology.com/news/20140414-dna_to_host_annual_meeting_in_orlando_may_1-4/2459272/The Dermatology Nurses' Association (DNA) will host its 32nd Annual Convention at the Walt Disney World Swan and Dolphin in Orlando, Fla., May 1-4. The convention offers educational tracks in Pediatric Dermatology, Cosmetic Dermatology, Wound Management, Professional Practice, Medical Dermatology, D
- Lithera to Present at the 13th Annual Needham Healthcare Conferencehttps://practicaldermatology.com/news/20140402-lithera_to_present_at_the_13th_annual_needham_healthcare_conference/2459280/Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced that George Mahaffey, President and Chief Executive Officer, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April
- April is Rosacea Awareness Monthhttps://practicaldermatology.com/news/20140401-april_is_rosacea_awareness_month/2459281/April is Rosacea Awareness Month and the National Rosacea Society encourages physicians and patients to raise awareness of the disease and its impact on affected individuals. This red-face disorder affects more than 16 million Americans between the ages of 30 and 60. It covers the spectru
- ZO Medical Products Launches in the Middle Easthttps://practicaldermatology.com/news/20140331-zo_medical_products_launches_in_the_middle_east/2459288/ZO Skin Health and Cellogique launched ZO products at the Dubai World Dermatology & Laser Conference Exhibition. Dr. Zein Obagi, board certified dermatologist, developed this product with hopes of representing his skin health principles. “These products empowe
- Joseph R. Williams Becomes Vice President of Global Marketing for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140326-joseph_r_williams_becomes_vice_president_of_global_marketing_for_caliber_imaging__diagnostics/2459292/Caliber Imaging & Diagnostics named Joseph R. Williams Vice President of Global Marketing. Williams past experience led him to this new position. Previously, he was Director of Market Development at AxsunTechnologies/Volcano Corporation, Senior Director of Global Marketing-Neurosurgery Di
- Merz Aesthetics To Launch New Physician Loyalty Programhttps://practicaldermatology.com/news/20140326-merz_aesthetics_to_launch_new_physician_loyalty_program_my_merz_select/2459293/Merz Aesthetics, a division of Merz North America, announced the upcoming launch of its completely new physician loyalty program, My Merz Select, which will go live on April 1, 2014. My Merz Select is a simple, transparent pro
- Galderma Announces Positive Results of Phase 3 Trials of Investigational Ivermectin 1% Targeting Papulopustular Rosaceahttps://practicaldermatology.com/news/20140325-galderma_announces_positive_results_of_phase_3_trials_of_investigational_ivermectin_1_targeting_papulopustular_rosacea/2459295/Galderma Laboratories, L.P. today announced the results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopustular (inflammatory) rosacea. The data were presented at a Late-Breaking session of the 72nd annual meeting of the American Ac